On Tuesday, December 4th, oral arguments were held before the U.S. Supreme Court in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA. The nation’s highest court will determine whether a secret sale of an invention, or a sale of a technology under terms that require the invention to remain confidential, triggers the on-sale bar under 35 U.S.C. § 102(a)(1), thereby preventing the invention from being patented. With this question squarely before the Supreme Court, several members of the legal industry who are watching this case offer their views on the major takeaways and the potential consequences of the Supreme Court’s decision, which will issue next year.
The post Industry Reaction to Helsinn Healthcare v. Teva Pharmaceuticals Oral Arguments appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Other Barks & Bites for Friday, October 4: Meta Hit with Class Action Copyright Infringement Lawsuit; Industry Leaders Ask for Clarification on Third-Party Litigation; EUIPO Applauds German Court Ruling on Misleading Invoices
- Patently Strategic Podcast: ITC Proofing Portfolios
- USPTO Says Order Terminating More than 3,000 Applications for Fraudulent Signatures is a Warning for Practitioners
- Export Control Requirements When Assigning Chinese Patents and Patent Applications to Foreign Entities
- Register of Copyrights Shira Perlmutter Jumps into the Great AI Debate at IPWatchdog LIVE